Randomized study of docetaxel or weekly paclitaxel followed by 5FU + epirubicin + cyclophosphamide as preoperative chemotherapy for primary breast cancer

Randomized study of docetaxel or weekly paclitaxel followed by 5FU + epirubicin + cyclophosphamide as preoperative chemotherapy for primary breast cancer - Randomized study of docetaxel or weekly paclitaxel followed by 5FU + epirubicin + cyclophosphamide as preoperative chemotherapy for primary breast cancer(KBCOG-06)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000000916

Enrollment

Registered

2007-12-01

Start date

2007-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary breast cancer

Interventions

docetaxel 75mg/m2 every three weeks, four cycles paclitaxel 80mg/m2 day1, 8, 15, every three weeks, four cycles

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1) histologically proven primary breast cancer with information about ER, PgR, Her2 status 2) clinical stage II or IIIA 3) no history of chemotherapy 4) no history of surgery against breast cancer 5) ECOG PS0, 1, 2 6) adequate organ function

Exclusion criteria

Exclusion criteria: 1) severe comorbidity 2) alergy to polysorbate 80 3) alergy to clemohol EL 4) active infection 5) severe peripheral neuropathy 6) alcohol intolerance 7) pregnant or lactating women

Design outcomes

Primary

Measure	Time frame
pathological complete response rate	—

Secondary

Measure	Time frame
clinical response rate, safety, breast conserving rate, progression free survival, overall survival	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026